Skip to main content
. 2021 Oct 20;13(11):1750. doi: 10.3390/pharmaceutics13111750

Figure 5.

Figure 5

Morphological assessment of the nasal MucilAir™ in vitro models treated with 10-fold diluted mometasone or placebo nasal spray, culture medium treated or untreated for 14 consecutive days using phase-contrast microscopy. The apical surface view is shown. Cell shedding is observed only at the periphery in the mometasone- and placebo-treated nasal MucilAir™ in vitro models on the last 2 days of the experiment (inserts, day 15). Asterisks indicate areas without cells. Scale bars, 100 µm.